However, although PI3K-AKT signalling is reduced in KRAS G12R-mutant pancreatic cancer, it is not fully eradicated, and instead PI3K is thought to act independently to KRAS G12R, through activity of the γ subunit, rather than p110α (Hobbs et al., 2020). This evidence concerns the gene KRAS and pancreatic neoplasm.